IPP Bureau

Pharma overhaul: EMA hails “Once-in-a-Generation” reform
Pharma overhaul: EMA hails “Once-in-a-Generation” reform

By IPP Bureau - December 16, 2025

The reform is set to modernise how medicines are developed, authorised, and made available across the EU

Sanofi flags delay in FDA review of Tolebrutinib for progressive multiple sclerosis
Sanofi flags delay in FDA review of Tolebrutinib for progressive multiple sclerosis

By IPP Bureau - December 16, 2025

Sanofi secures two breakthrough nods in China for rare blood disorders
Sanofi secures two breakthrough nods in China for rare blood disorders

By IPP Bureau - December 16, 2025

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia

Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome
Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome

By IPP Bureau - December 16, 2025

The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste

Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline
Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline

By IPP Bureau - December 16, 2025

The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.

Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod

By IPP Bureau - December 16, 2025

The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort

Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies
Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies

By IPP Bureau - December 16, 2025

Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD

Anova launches AI-powered patient matching platform to speed clinical trial enrollment
Anova launches AI-powered patient matching platform to speed clinical trial enrollment

By IPP Bureau - December 16, 2025

Clinical trial enrollment has long been a bottleneck in drug development

Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully
Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully

By IPP Bureau - December 15, 2025

This is also an important milestone in our product strategy for our expansion into the larger Latin American market

Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga

By IPP Bureau - December 15, 2025

Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility

Eiko LifeSciences to acquire 51% stake in SSM Formulations
Eiko LifeSciences to acquire 51% stake in SSM Formulations

By IPP Bureau - December 15, 2025

The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules

Anil Koul joins Mankind Pharma as Group Chief Scientific Officer
Anil Koul joins Mankind Pharma as Group Chief Scientific Officer

By IPP Bureau - December 15, 2025

More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline

Akums launches advanced Gabapentin ER for PHN management with RetenEx technology
Akums launches advanced Gabapentin ER for PHN management with RetenEx technology

By IPP Bureau - December 15, 2025

Thermo Fisher Scientific appoints Anoopa Menon as Director
Thermo Fisher Scientific appoints Anoopa Menon as Director

By IPP Bureau - December 14, 2025

In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation

Novartis appoints Vrinda Taneja as Director – People & Organisation, International India
Novartis appoints Vrinda Taneja as Director – People & Organisation, International India

By IPP Bureau - December 14, 2025

Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D

Latest Stories

Interviews

Packaging